Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DE5VG3
|
|||
| Drug Name |
MCO-010
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Retinitis pigmentosa [ICD-11: 9B70; ICD-10: H35.5] | Phase 2 | [1] | |
| Company |
NanoScope Technologies Bedford, TX
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04945772) A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.